Names without a link are companies not yet registered in OpenBizGraph
§05
Network
NETWORK
Loading the relationship graph...
Drag to move · click to open
§06
History
54 EVENTS
Established EPS Tokyo Co., Ltd. with the purpose of developing and selling software related to clinical trials. With a focus on developing the "Treatment Allocation and Trial Progress Management System" and the "GCP Management System", we started EPS Tokyo with three employees, aiming to operate clinical trials scientifically and ethically.
Changed its corporate name to Fudan Seiei Co., Ltd.
Since its founding in 1991, the EPS Group has expanded services related to pharmaceutical development and has continued to grow. With business expansion, both sales and employee numbers have increased year by year, and the annual average growth rate (CAGR) from October 2021 to September 2022 was 10.5%.
Established EPS Tokyo Co., Ltd.
Changed the company name to Fudan Sōei Corporation.
Changed its corporate name to EPS Tokyo.
Name changed to EPS Tokyo.
Started case registration and allocation services related to clinical trials, entering the CRO (Contract Research Organization) business.
Contracted to develop support systems for two large-scale clinical trials of the Ministry of Health, Labour and Welfare's pharmaceutical epidemiology research ("MEGA Study" and "ATHEROMA Study"). We also started data center operations for both trials.
Started clinical trial-related case registration and allocation services, entering the CRO (contract research organization) business.
Developed a large-scale clinical trial support system related to Ministry of Health, Labour and Welfare drug epidemiology research.
Changed its corporate name to EPS Co., Ltd.
Name changed to EPS Corporation.
Started CRO and software development businesses in China. As the first full-fledged CRO in China, we began operations in Shanghai.
Started an SMO (Site Management Organization) business to support clinical trial-related activities at medical institutions.
Launched an SMO (study site management organization) business that supports clinical trial-related activities at medical institutions. After several mergers, the EPS Group's SMO business has grown to become the industry's market leader.
Started CRO and software development business in China.
As China's first full-fledged CRO, started operations in Shanghai.
Started SMO (Clinical Trial Site Management Organization) business supporting clinical trial-related activities at medical institutions.
Started SMO business supporting clinical trial-related activities at medical institutions. After several mergers, EPS Group's SMO business grew to become the industry's market leader.
Started a CSO (Contract Sales Organization) business to handle MR (Medical Representative) activities for pharmaceutical companies.
Started CSO (Contract Sales Organization) business handling pharmaceutical companies' MR activities.
Changed its corporate name to IPS Co., Ltd.
Listed shares on JASDAQ. Became the first listed company as a CRO.
Changed the company name to EPS Corporation. Listed its shares on JASDAQ, becoming the first listed company as a CRO.
Name changed to I.P.S. Corporation.
Listed on JASDAQ.
Started CRO business in Southeast Asia.
Started CRO business in Southeast Asia.
Listed shares on the First Section of the Tokyo Stock Exchange.
Listed on First Section of Tokyo Stock Exchange.
Started pharmaceutical sales business in China. Manufacturing is also conducted mainly in Shanghai, and the company handles several drugs, including a top-share product in the HPV (human papillomavirus) treatment field for obstetrics and gynecology.
Celebrated China Espline sales.
Started pharmaceutical sales business in China.
Manufactures centered in Shanghai and handles several drugs, including top-share products in the gynecology HPV (human papillomavirus) treatment field.
Changed company name to EPSHD Corporation.
Transitioned to a holding company structure and changed the company name to EPS Holdings Corporation.
Established a business segment structure in conjunction with the holding company formation.
Changed the company name to EPSHD Corporation. Transitioned to a holding company structure and changed the company name to EPS Holdings Corporation. Established a business segment structure in conjunction with the holding company formation.
Name changed to EPSHD Corporation.
Transitioned to a holding company structure and changed name to EPS Holdings Corporation.
Entered into a capital and business partnership agreement with Suzuken Co., Ltd.
Entered into a capital and business partnership agreement with Suzuken Co., Ltd.
Participated in joint development of a DNA vaccine for COVID-19.
Participated in joint development of a DNA vaccine for COVID-19.
30th anniversary of founding.
Launched a new three-year medium-term management plan, 'SHINYO'.
30th anniversary of founding. Launched a new three-year medium-term management plan, 'SHINYO'.
30th anniversary of founding.
Completion of the company's building, Chikudo Terrace.
In 2022, to adapt to changing environments for future clinical trials and other activities and to enable agile strategic decisions and management, we established EPNextS Co., Ltd., which oversees the three core businesses. We look forward to the EPS Group taking flight toward a new stage as a solution provider.
Completion of Chikudo Terrace.
EPNextS Co., Ltd., which oversees core businesses (CRO, SMO, CSO), began full operation.
EPNextS, a company that oversees the core business (CRO, SMO, CSO), has begun full operation.
§07
News
10 ARTICLES
Joint Verification of AI for Pharmaceutical Document Creation and Review
EP PharmaLine and Fujifilm Systems Services are jointly verifying an AI platform that supports the creation and review of documents related to medical pharmaceuticals. The verification, which began in July 2026, has confirmed its effectiveness in improving work efficiency and leveraging the knowledge and know-how of experienced personnel. They will continue the verification to assess its impact on actual work time and the standardization of quality.
Change of Executive Structure of Major Companies in the EPS Group
EPS Holdings Co., Ltd. and the major companies of the EPS Group announced that they had changed their executive structure as of October 1, 2026. They have disclosed the structure of the chairman, president, vice president, and executive officers of EPS Holdings.
EPS Holdings and Suzuken Group Deepen Strategic Partnership
EPS Holdings and the Suzuken Group have begun discussions on a business partnership and a review of their capital structure to create new value in healthcare and related fields.
EPS Group Establishes Basic AI Policy
EPS Holdings has established the EPS Group Basic AI Policy to promote responsible AI use across the group. Group companies will use the policy to advance AI adoption and governance, contributing to the development of the healthcare industry.
EPS Holdings Group's Response to the Kumamoto Earthquake
EPLink Corporation, a group company of EPS Holdings, announced its response to the 2026 Kumamoto Earthquake. We express our sympathy to the victims and wish for early recovery.
EP PharmaLine obtains ISMS and QMS certifications
As of July 29, 2026, EP PharmaLine has obtained ISO/IEC 27001 certification for its Information Security Management System and ISO 9001 certification for its Quality Management System. The scope of ISO/IEC 27001 covers the entire company, while ISO 9001 applies to designated departments such as the business headquarters.
EP PharmaLine Strengthens System with ISO Certification
EP PharmaLine obtained ISO/IEC 27001 certification for information security and ISO 9001 certification for quality management on July 29, 2026. This aims to strengthen the company's overall management system. The certifications were accredited by the Japan ISO Examination Registration Center and the Japan Certification Association.
Notice of EPS Group Founding Anniversary Holiday Closure
EPS Holdings Inc. will be closed all day on Friday, May 29, 2026, for the founding anniversary holiday. We apologize for any inconvenience caused to our customers and appreciate your understanding.
Notice of EPS Holdings Directors and Officers Changes
EPS Holdings Co., Ltd. announced a change of directors on April 1, 2026. Mr. Kiyohiro has been appointed as Chairman and Representative Executive Officer, and Mr. Tatsu Nagaoka has been appointed as President and Representative Executive Officer. Changes have also been made to other directors.
Notice of Headquarters Relocation of EPS Group Companies
EPS Holdings Group companies will relocate their headquarters. EPLink Corporation will move to the new headquarters on April 13, 2026, and EP Trading will also relocate in the same year. Details about the headquarters address and business start date are included.
§08
Public records
GOV
National Tax Agency basic information4011101095073
Source: National Tax Agency Corporate Number Publication Site, basic three items
Trade name
ＥＰＳホールディングス株式会社
Trade name (kana)
イーピーエスホールディングス
Name in English
Corporation type
301
Address
〒162-0815 東京都新宿区筑土八幡町２番１号
Postal code
1620815
Prefecture code
13
City code
104
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2021-05-20
Update date
2025-04-18
Change date
2025-04-01
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record
1
Excluded from search
0
Processing type
12
Correction type
0
Trade name image ID
Address image ID
Sequence number
1805117
METI gBizINFO4011101095073
Source: gBizINFO (Ministry of Economy, Trade and Industry)
